The purpose of SMA Europe is to provide a framework to stimulate collaboration and accelerate translational research pathways in SMA and promote patient care.

  1. Biogen releases statement on CHERISH data

    Biogen releases statement on CHERISH dataAt our request, Biogen sent us a community update on the end of study results from CHERISH, the Phase 3 trial evaluating nusinersen for the treatment of individuals with later-onset SMA, which have now been published in the New England Journal of Medicine (NEJM).

    The full manuscript entitled, “Nusinersen Versus Sham Control in Later-Onset Spinal Muscular Atrophy” can be found in the 15th February 2018 issue of The New England Journal of Medicine.

    Please see the community update for Biogen’s news on this.

    For more information